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http://dx.doi.org/10.1016/j.ccr.2014.07.009SUMMARYIn a genome-wide survey on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA) in
2,394 tumor specimens from 12 cancer types, we found that about 21.8% of lncRNA genes were located in
regions with focal SCNAs. By integrating bioinformatics analyses of lncRNA SCNAs and expression with
functional screening assays, we identified an oncogene, focally amplified lncRNA on chromosome 1
(FAL1), whose copy number and expression are correlatedwith outcomes in ovarian cancer. FAL1 associates
with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a num-
ber of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of
p21. FAL1-specific siRNAs significantly inhibit tumor growth in vivo.INTRODUCTION subset of SCNAs contributes to tumorigenesis. Systemic ana-Cancer genomes are highly disorganized and harbor numerous
somatic copy-number alterations (SCNAs) (Beroukhim et al.,
2010; Zack et al., 2013). Although the majority of the copy num-
ber abnormalities are the consequence of genomic instability, aSignificance
Although up to 70% of the human genome is transcribed to
miRNAs, recent studies of lncRNAs suggest that they may rep
tumorigenesis. However, research on the oncogenic roles of lnc
description of lncRNA SCNAs in 12 types of cancer and descri
oncogenic activity. Using this approach, we identified FAL1 as
lecular mechanism underlying the oncogenic activity of FAL1
cancer prognostic marker and therapeutic target.
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tional screening have been successfully applied to identifying
cancer-driving SCNA loci that encode proteins (Beroukhim
et al., 2010; Zack et al., 2013). However, protein-coding
sequences occupy less than 2% of the human genomeRNA, only 2% carries protein-coding genes. In addition to
resent another important class of nonprotein regulators of
RNAs is limited. In the current study, we provide an in-depth
be an integrated approach of identifying lncRNA genes with
an oncogenic lncRNA. Our studies have elucidated the mo-
and provide proof-of-concept evidence for using FAL1 as a
.
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and many focal SCNAs in cancer have been mapped to ‘‘pro-
tein-coding gene desert’’ regions (Beroukhim et al., 2010; Zack
et al., 2013).
Recent advances in high-throughput sequencing technology
have revealed that the majority (70%) of the human genome
is transcribed to RNA, generating many thousands of noncoding
transcripts (Derrien et al., 2012; Djebali et al., 2012). Long
noncoding RNAs (lncRNAs) are operationally defined as RNA
transcripts that are larger than 200 nt but do not appear to
have protein-coding potential (Batista and Chang, 2013; Gutt-
man and Rinn, 2012; Karreth and Pandolfi, 2013; Lee, 2012; Lie-
berman et al., 2013; Ørom and Shiekhattar, 2013; Prensner and
Chinnaiyan, 2011; Ulitsky and Bartel, 2013). Similar to protein-
coding transcripts, the transcription of lncRNAs is subject to
typical histone-modification-mediated regulation, and lncRNA
transcripts are processed by the canonical spliceosomemachin-
ery. Compared with their protein-coding counterparts, lncRNA
genes are composed of fewer exons, under weaker selective
constraints during evolution, and in relatively lower abundance.
In addition, the expression of lncRNAs is strikingly cell type and
tissue specific and, in many cases, even primate specific. To
date, most of the well-characterized lncRNAs have been discov-
ered serendipitously. The investigations on this small cohort of
lncRNAs have demonstrated that these noncoding transcripts
can serve as scaffolds or guides to regulate protein-protein or
protein-DNA interactions (Engreitz et al., 2013; Gupta et al.,
2010; Huarte et al., 2010; Jeon and Lee, 2011; Simon et al.,
2013; Tsai et al., 2010; Yang et al., 2011, 2013b), as decoys to
bind proteins (Di Ruscio et al., 2013; Hung et al., 2011; Tripathi
et al., 2010, 2013) or microRNAs (miRNAs) (Hansen et al.,
2013; Memczak et al., 2013; Poliseno et al., 2010; Tay et al.,
2011), and as enhancers to influence gene transcription, when
transcribed from the enhancer regions (enhancer RNA) (Kim
et al., 2010; Li et al., 2013; Wang et al., 2011) or their neighboring
loci (noncoding RNA activator) (Lai et al., 2013; Ørom et al.,
2010). The biological processes affected by lncRNAs include
cell proliferation (Hung et al., 2011; Tripathi et al., 2013), differen-
tiation (Guttman et al., 2009; Guttman et al., 2011; Kretz et al.,
2013; Loewer et al., 2010; Ulitsky et al., 2011), migration (Gupta
et al., 2010; Ling et al., 2013; Ørom et al., 2010; Yang et al.,
2013a), immune response (Carpenter et al., 2013; Gomez et al.,
2013), and apoptosis (Huarte et al., 2010), all of which have
been implicated in tumorigenesis. In addition to being higher de-
regulated in tumors (Du et al., 2013; Gupta et al., 2010; Prensner
et al., 2011), lncRNAs have been found to act as tumor suppres-
sors or oncogenes (Gupta et al., 2010; Ji et al., 2003; Ling et al.,
2013; Pasmant et al., 2007; Prensner et al., 2011, 2013; Yang
et al., 2013b; Yildirim et al., 2013). To characterize the landscape
of lncRNA gene SCNAs across cancers, we repurposed the SNP
microarray results from a total of 2,394 tumor specimens taken
from 12 cancer types (Beroukhim et al., 2010) and analyzed the
SCNAs of 13,870 lncRNA gene loci.
RESULTS
lncRNAs Exhibit Frequent SCNAs in Human Cancer
We analyzed the SNP arrays of a total of 2,394 tumor specimens
from 12 cancer types in the Tumorscape database created byCathe Broad Institute (Beroukhim et al., 2010) (Table S1 and Fig-
ure S1A available online). The genomic locations of 13,870
lncRNAs (Table S2) were retrieved from an evidence-based
lncRNA annotation provide by the GENCODE Consortium (Der-
rien et al., 2012), and the SCNA frequency of each lncRNA-
containing locus was calculated. This revealed that the more
frequently a lncRNA has a copy-number gain in a given tumor
type, the less likely it would also have a high frequency of
copy-number loss in the same tumor type (Figure S1B). As a
result, when we define high-frequency gains or losses as alter-
ations that take place in more than 25% of specimens from a
given tumor type, few lncRNAs had both high-frequency gain
and loss in the same type of tumor. Across the 12 tumor types,
there were on average 12.0% and 7.6% of lncRNAs with high-
frequency (i.e., in >25% of tumors) gain and loss, respectively
(Figures 1A–1C; Table S3). Although small cell lung cancer had
the largest number of high-frequency lncRNASCNAs, myelopro-
liferative disorder had none (Figures 1B and 1C). Similar to the
overall genomic alteration profiles, lncRNA SCNA profiles were
cancer-type specific (Figure 1B; Figure S1A). Additionally, we
analyzed the SNP arrays using a second lncRNA annotation
generated by Cabili et al. (2011) (Table S2) and found the lncRNA
SCNA frequency and tumor-type specificity were similar to
that analyzed with GENCODE annotation (Figures S1C–S1E
and Table S3). To further validate these findings, we acquired
SNP arrays from The Cancer Genome Atlas (TCGA) project
and analyzed lncRNA SCNAs in breast cancer. The lncRNA
SCNA profiles in breast cancer samples from TCGA data sets
were almost identical to those from the Broad Institute database
(Figure S1F).
Two types of SCNAs are present in cancer genomes: those
confined to a small genomic region are termed focal alterations,
and those encompassing a large fragment, or even a whole
chromosomal arm, are referred as broad (arm-level) alterations.
Because focal alterations contain only a handful of genes
and often exhibit high-amplitude variation, analyses of these
alterations have led to the successful identification of cancer-
causing genes (Beroukhim et al., 2010; Du et al., 2013). To
screen for lncRNAs that may act as driver genes in tumorigen-
esis, we mapped lncRNA loci to 158 independent focal
genomic alteration peaks (76 gains and 82 losses) that have
been previously identified (Beroukhim et al., 2010). Totals of
1,064 and 1,953 lncRNAs were located in the regions with focal
gains and losses, respectively (Tables S4 and S5). Although
995 lncRNAs were located in focal SCNA regions where can-
cer-associated protein-coding genes reside, we identified
2,022 (14.6%) lncRNAs in focal alteration regions that contain
no known cancer-associated protein-coding genes (Tables S4
and S5). Importantly, within the top 20 most significant
focal alteration peaks (Beroukhim et al., 2010), we identified
56 lncRNAs in focal gain regions and 132 lncRNAs in focal
loss regions (Figure 1D). We reasoned that the lncRNAs that
demonstrate high-frequency genomic alterations and/or reside
in focal alteration loci are candidates for cancer-causing
lncRNAs.
lncRNAs Are Widely Expressed in Human Cancer Cells
Because lncRNAs exert their functions as RNAs, we reasoned
that the presence of RNA transcripts in cells should be ancer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inc. 345
Figure 1. SCNAs of lncRNA in Cancers
(A) A genome-wide view of SCNAs in lncRNA-containing loci in cancers. Each track shows the frequency of lncRNA SCNAs in one cancer type. Red indicates
gain; blue indicates loss. The outer and inner tracks represent cancer types 1 and 12, respectively.
(B) Heatmap of SCNA frequencies of lncRNA genomic loci in cancers. Each row represents one lncRNA, ordered by genomic location. Left, frequency of gain
(red); right, frequency of loss (blue).
(C) Percentages of lncRNAs with significant copy-number alteration (>25% of specimens) in cancers.
(D) The lncRNAs and protein-coding genes in the top 20most significant focal gain (left) or loss (right) peaks across cancers. The numbers of protein-coding genes
(left) and lncRNAs (right) in each peak are indicated in parentheses. The independent focal genomic alteration peaks and the numbers of protein-coding genes in
each peak were previously identified by the Tumorscape Project (Beroukhim et al., 2010).
See also Figure S1 and Tables S1, S2, S3, S4, S5, S6, and S7.
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the genomic loci harboring lncRNAs with no detectable RNA
transcripts are likely to be passenger events. We profiled 40
established cancer cell lines (across five cancer types) from
the NCI60 cell line panel (Table S6) using a custom 60-mer oligo-
nucleotide microarray with a total of 14,262 probes for 2,965
lncRNAs (an average of 5 probes for each lncRNA; Table S7),
which were initially identified using the GENCODE annotation
(Ørom et al., 2010). Probes for 11,081 protein-coding genes
were also included in our microarray as controls. Overall,
41.7% of the lncRNA and 82.9% of the protein-coding gene
probes were detected in 10 (25%) or more of the 40 cell lines;
23.8% of the lncRNA and 4.9% of the protein-coding gene
probes were not detected in any cell line (Figure S1G). Among
all the lncRNAs studied, about 17.8% were expressed in all 40
cancer cell lines. To validate the RNA expression results frommi-
croarray, we measured the RNA expression of 6 well-known
lncRNAs in these cancer cell lines by quantitative RT-PCR
(qRT-PCR) and found that there were strong correlations be-
tween the RNA expression measured by microarray and by
PCR (Figure S1H). These findings demonstrate that lncRNAs
are indeed widely expressed in cancers. Together, the cancer-
cell-specific RNA expression information and the lncRNAs
SCNA in multiple types of tumors can help us narrow down the
list of cancer-causing lncRNA candidates by eliminating
lncRNAs that do not express in cancer cells.346 Cancer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier IncClinically GuidedGenetic Screening Identified FAL1 as a
Potential Oncogenic lncRNA
Next, we used the information obtained from the above genomic
and transcriptomic analyses to select oncogenic lncRNA candi-
dates for functional validation. The three criteria for candidate
selection were as follows: (1) the lncRNA copy-number gain is
observed in more than 25% of the samples in at least one type
of tumors, (2) the lncRNA is located in a focal amplicon, and (3)
the RNA expression of the candidate lncRNA is detected in
more than 50% of cancer cell lines. The functional readout for
the initial screening was in vitro clonogenicity. We hypothesized
that short hairpin RNAs (shRNAs) targeting true oncogenic
lncRNAs should greatly reduce the clonogenicity of cells, and
shRNAs targeting bystander lncRNAs will have no effect. To
minimize the possibility of observing off-target effects, we de-
signed two independent shRNAs for each lncRNA candidate.
In the initial clonogenic screening (Figure 2A), 37 lncRNA candi-
dates were screened, and we found that both shRNAs targeting
ENSG00000228126 (focally amplified lncRNA on chromosome 1
[FAL1]), a lncRNA in a focal amplicon on chromosome 1q21.2
(Figures S2A and S2B), significantly reduced the clonogenicity
of A2780 cells in a dose-dependent manner. Compared with
FAL1 shRNA1, shRNA2 was more efficient in knocking down
endogenous FAL1 expression (Figure 2B) and had a greater ef-
fect on inhibiting cell growth and colony formation (Figures 2A
and 2B). Similar results were also observed in MDA-MB-231.
Figure 2. Identification and Validation of FAL1 as a Potential Oncogenic lncRNA
(A) Representative results from clonogenic shRNA screening for oncogenic lncRNAs in A2780 (in 24-well plates). (Bottom)Wells with colonies expressing controls
and FAL1 hairpins.
(B) Relative expression of FAL1 (left) and growth curve (right) of A2780 cells expressing control and FAL1 shRNAs.
(C) Growth curves of seven cancer cell lines transfected with control or FAL1 siRNAs. The FAL1 SCNA status of each cell line is indicated as a blue (gain) or gray
(normal) rectangle, and the relative FAL1 expression in parental cells is indicated by the intensities of the pink rectangles.
(D). Soft-agar assay with cells expressing control and FAL1 shRNAs (in 6-well plates).
(E) In vivo xenograft tumor growth curves of A2780 and MDA-MB-231 cells expressing control and FAL1 shRNAs.
(F) Schematic diagram of the experimental design of testing the oncogenic potential of FAL1.
(G) The expression of Myc or Ras in HOSE cells transduced with FAL1 alone or in combination with Myc or Ras.
(H and I) The representative result of soft-agar assay (H) and the corresponding quantification (I) on control cells and cells expressing FAL1 alone or in combination
with Myc or Ras.
Error bars indicate SD. *p < 0.05. See also Figure S2.
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in seven more cell lines that have a wide range of FAL1 expres-
sion and various status of FAL1 SCNA. With the exception of
SKOV3 cells, which have normal copy number and low RNACaexpression of FAL1, all other cell lines were more or less depen-
dent on the expression of FAL1 for their growth (Figure 2C). Soft-
agar assays further demonstrated that the expression of FAL1
shRNAs significantly inhibited the anchorage-independentncer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inc. 347
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Oncogenic lncRNA FAL1 Represses p21 Expressiongrowth of cancer cells (Figure 2D). Next, we demonstrated that
the expression of FAL1 shRNAs significantly suppressed the
growth of subcutaneous tumors formed by A2780 or MDA-
MB-231 cells in nude mice (Figure 2E).
We examined if FAL1 expression is sufficient to promote trans-
formation. We forced the expression of full-length FAL1 cDNA
(Figures S2C and S2D) in two independent batches of primary
human ovarian surface epithelial (HOSE) cells and further trans-
duced these FAL1-modified cells with Myc or Ras and their cor-
responding controls (Figures 2F and 2G). The oncogenicity of
FAL1 alone or in combination with Myc or Ras was evaluated
in soft-agar assays. Although control HOSE cells form no colony
in soft agar, cells expressing FAL1 were able to form some col-
onies, although compared with those formed with Myc or Ras
cells, the FAL1 colonies were smaller and in fewer numbers (Fig-
ures 2F and 2G). Intriguingly, HOSE cells expressing FAL1 in
combination with Myc (or Ras) formed significantly more col-
onies than their single-gene expressing counterparts (Figures
2H and 2I; Figure S2E–S2Q). In aggregate, by integrating
genomic and transcriptomic analysis with functional screening,
we have successfully identified FAL1 as a potential oncogenic
lncRNA.
Interestingly, FAL1 amplicon also contains a known protein-
coding oncogene,MCL1 (Beroukhim et al., 2010). We compared
the mRNA levels of MCL1 and five other genes within the FAL1
locus in control and FAL1 shRNA expressing A2780 cells and
found that knocking down FAL1 did not affect the expression
of any of these neighboring genes (Figure S2R). This finding sug-
gests that FAL1 does not control the transcription of its neigh-
boring genes; as such, the function of FAL1 is likely independent
to regulation ofMCL1 expression. It has been documented that a
cluster of oncogenic lncRNAs, including PCAT-1, CCAT2, and
CARLo-5, coamplify with MYC; yet they promote tumor growth
via Myc-independent mechanisms (Kim et al., 2014; Ling et al.,
2013; Prensner et al., 2011).
Expression and SCNA of FAL1 Are Associated with
Clinical Outcomes in Patients with Ovarian Cancer
An in-depth investigation of the SNP arrays revealed that the fre-
quency of FAL1 copy-number gain was remarkably high (49.7%)
in epithelial tumors but much lower in neural (<19%) and hema-
tologic (<6%) tumors (Figure 3A). Importantly, FAL1 gene resides
at a significant focal amplicon (Q < 0.25) on chromosome 1q21.2
in epithelial cancers (Figures 3A and 3B). To confirm these obser-
vations, we measured the copy number of FAL1 in 99 cancer cell
lines using quantitative PCR and observed FAL1 copy-number
gain in 46% of the cell lines (Figure 3C; Table S8). We then ex-
tracted the FAL1 RNA expression data from the aforementioned
custom RNA array containing 40 cancer cell lines and found a
significant and positive correlation between the genomic copy
number and RNA expression of FAL1 (R = 0.472, p = 0.002; Fig-
ure 3D). It is also worth noting that several cell lines without FAL1
amplification express high-level FAL1 RNA. This observation
suggests that FAL1 RNA overexpression may be a common
phenomenon in cancer cells and that mechanisms other than
genomic amplification are present to cause FAL1 RNA overex-
pression in cancer (Figure 3D).
To evaluate the clinical significance of FAL1 in cancer,
we characterized its expression and cellular location by in situ348 Cancer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inchybridization (ISH) using a FAL1-specific probe in a cohort of
ovarian cancer specimens (n = 181, including 53 early-stage
cases and 128 late-stage cases; Table S9). A FAL1-positive
signal was detected in more than 93% of the specimens.
Although 31.6% of the samples exhibited a strong signal,
37.5% and 23.9% had intermediate and weak signals, respec-
tively (Figure 3E). FAL1-positive samples also exhibited a nu-
clear-enriched staining pattern, with a weak signal in cytoplasm.
Similar staining patterns were also observed in cancer cell lines.
We also characterized subcellular localization of FAL1 by cell
fractionation followed by qRT-PCR and observed the majority
of FAL1 RNA in the nuclear (Figure S3). Next, we measured
FAL1 RNA expression and genomic copy number using qPCR
in ovarian tumors and found that both the FAL1 RNA expression
and genomic copy number in late-stage tumors were signifi-
cantly higher than those in early-stage tumors (Figures 3F and
3G). Consistent with the observation from cell lines, there was
a strong and positive correlation between FAL1 RNA expression
and its genomic copy number in the ovarian tumor specimens
(R = 0.577, p < 0.001; Figure 3H). After stratifying the 128 late-
stage ovarian cancer patients with FAL1 RNA expression (cutoff,
median expression) or gene amplification status, we found that
both higher expression of FAL1 RNA and genomic gain of
FAL1 gene were significantly associated with decreased survival
in patients (p < 0.0001 and p = 0.03, respectively; Figure 3I).
Taken together, these clinical findings demonstrated that gene
amplification and RNA overexpression of FAL1 occur frequently
in epithelial cancer and are both associated with tumor progres-
sion in ovarian cancer.
FAL1 Associates with BMI1 Protein and Regulates
Its Stability
To explore the molecular mechanisms underlying the oncogenic
activity of FAL1, we sought to use RNA pull-down assay to iden-
tify proteins associatedwith FAL1. Briefly, biotinylated full-length
FAL1 or antisense transcript (negative control) synthesized by
in vitro transcription was incubated with the nuclear lysate
from A2780 cells, and coprecipitating proteins were isolated
with streptavidin-agarose beads (Figure 4A). The RNA-associ-
ating proteins were resolved on SDS-PAGE gel, and the bands
specific to FAL1 were identified. BMI1, a 37 kD core subunit of
the polycomb repressive complex 1 (PRC1) (Schuettengruber
et al., 2007), was initially identified as a protein that was present
only in FAL1-associated samples. To validate the association
between BMI1 and FAL1, we subjected the lncRNA-pull-down
protein samples to western blot with BMI1 antibody. A strong
signal was observed in proteins pulled down with FAL1 RNA
but not in samples bound with either antisense FAL1 or an unre-
lated fragment of HOTAIR (Figure 4B). To further confirm the
interaction between FAL1 and BMI1, we performed an RNA-
immunoprecipitation (RNA-IP) assay, in which the RNA-BMI1
complex was immunoprecipitated using a BMI1 antibody. The
amount of FAL1 RNA in the coprecipitate was then measured
by qRT-PCR. Comparedwith the immunoglobulin G (IgG)-bound
sample, the BMI1-antibody-bound complex had a significant in-
crease in the amount of FAL1RNA (Figures 4C and 4D). As nega-
tive controls, we also quantified the levels of two unrelated
lncRNAs, ENST00000457448 and HOTAIR, in the complexes
coprecipitated by IgG or the BMI1 antibody. No significant.
Figure 3. Characterization of FAL1 Copy Number and RNA Expression in Cancers
(A) SCNAs of FAL1 locus in cancers. Focal amplicons were identified by GISTIC analysis (Tumorscape).
(B) Copy-number profiles of chromosome 1q from breast and ovarian tumor specimens. Each sample is represented with a vertical line, and the positions of FAL1
are noted with black horizontal lines. Red indicates gain; blue indicates loss.
(C) Copy numbers of FAL1 in cancer cell lines (n = 99) were measured by qPCR.
(D) A correlation between FAL1 gene copy number and RNA expression was observed in 40 cell lines.
(E) FAL1 expression visualized by ISH in ovarian cancer.
(F) FAL1 expression levels in early- and late-stage ovarian cancer specimens.
(G) Copy number of FAL1 in the same cohort.
(H) A correlation between FAL1 copy number and expression was observed in ovarian cancer specimens.
(I) Survival curves of late-stage ovarian cancer patients with high and low FAL1 RNA expression (top) or different genomic SCNA status (bottom).
See also Figure S3 and Tables S8 and S9.
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Figure 4. FAL1 Associates with the BMI1 Protein and Regulates Its Stability
(A) A schematic representation of RNA pull-down.
(B) Western blot of BMI1 expression in 5% input and protein complexes pulled down by FAL1, antisense control, or unrelated control HOTAIR fragment from
nuclear extracts.
(C) A schematic representation of an RNA immunoprecipitation assay.
(D) Results from RNA-IP and subsequent qRT-PCR assays. (Top) Relative quantification of FAL1, HOTAIR, and ENST00000457448 in RNA-protein complexes
immunoprecipitated with IgG or BMI1 antibodies from nuclear extracts. (Bottom) Representative western blot of BMI1 in the corresponding samples.
(E) Deletion mapping of BMI1-binding domain in FAL1. (Left) The schematic diagram of full-length and deleted fragments of FAL1; (right top) in vitro transcribed
full-length and deleted fragments of FAL1 showing correct sizes; (right bottom) western blot of BMI1 in protein samples pulled down by different FAL1 fragments.
(F) Expression of FAL1 and BMI1 in A2780 (left) and MCF-7 (right) cells expressing shRNAs targeting these two genes.
(G) The expression of Ring1A, Ring1B, and ubiqintination of H2AK119 in A2780 (left) and MCF7 (right) cells expressing control and FAL1 shRNAs.
(H) The levels of BMI1, Ring1A, and Ring1B in the cytoplasmic fraction, the soluble nuclear fraction, the chromatin-bound insoluble nuclear fraction of A2780 cells
expressing control and FAL1 shRNAs. Tubulin and H3 were used as cytoplasmic and chromatin-bound loading controls, respectively.
(I) The expression levels of BMI1, Ring1A, and Ring1B in control and FAL1 knockdown cells treated with CHX.
(J) Western blot (left) and quantification (right) of BMI1 expression in control and FAL1 knockdown cells treated with vehicle control or MG132.
(K) Western blot of BMI1-associated ubiquitination in control and FAL1 knockdown cells treated with MG132.
Error bars indicate SD. *p < 0.05. See also Figure S4.
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(Figure 4D). Furthermore, using a series of deletion-mapping an-
alyses, we identified a 116 nt region in the middle of the FAL1
transcript (nt 296–411) as a major BMI1-binding domain, which
is both required and sufficient for FAL1-BMI1 association (Fig-
ure 4E). Taken together, these results demonstrate that BMI1
is a FAL1-associated protein.
Next, we explored themolecular consequences of FAL1-BMI1
association. Although downregulation of BMI1 mRNA expres-
sion via BMI1 shRNAs had no effect on FAL1 RNA levels, ex-
pressing FAL1 shRNAs significantly reduced the protein level,
but not the mRNA level, of BMI1 (Figure 4F). The level of two
other PRC1 core proteins, Ring1A and Ring1B, were similar in
control and FAL1-knockdown cells, and the level of ubH2AK119
was much lower in FAL1-knockdown cells than in control cells
(Figure 4G). Although we detected a weak signal of Ring1B in
the FAL1-protein complex from lncRNA pull-down assay, the
signal of BMI1 in FAL1-protein complex was much stronger
than that of Ring1B, and FAL1-mediated pull-down significantly
enriched BMI1 but not Ring1B protein (Figure S4A). This obser-
vation suggests that the FAL1-BMI1 association may help spe-
cifically stabilize BMI1 protein. Additionally, we fractionated con-
trol and FAL1-knockdown cells and analyzed the protein levels
of BMI1, Ring1A, and Ring1B in the cytoplasm, the soluble nu-
clear fraction, and the insoluble, chromatin-bound fraction. As
shown in Figure 4H, there was a marked decrease of chro-
matic-bound BMI1, Ring1A, and Ring1B proteins in FAL1-
knockdown cells than in controls. Concomitantly, there was a
slight increase of these three PRC1 proteins in the soluble nu-
clear fraction in FAL1-knockdown cells than in control cells (Fig-
ure 4H). To further explore the mechanism of FAL1-mediated
BMI1 regulation, we treated A2780 cells with cycloheximide
(CHX) and analyzed the stabilities of BMI1, Ring1A and Ring1B
in response to FAL1 downregulation. Although the half-lives of
Ring1A and Ring1B were not significantly affected by FAL1
knockdown, the half-life of BMI1 was much shorter in FAL1
knockdown cells than in controls (Figure 4I). The half-life of
MDM2, a protein unrelated to PRC1 complex, was not affected
by FAL1 knockdown, suggesting that FAL1 shRNA expressions
does not affect protein half-lives globally (Figure S4B). In agree-
ment with this observation, whenMG132was added into the cul-
turemedium to inhibit proteasome degradation, the endogenous
BMI1 protein expression in FAL1 knockdown cells was signifi-
cantly increased and reached a level that was comparable to
that in control cells (Figure 4J), and higher BMI ubiquitination
levels were also observed in FAL1 knockdown cells treated
with MG132 (Figure 4K). In aggregate, these observations sug-
gested that FAL1 expression is important in regulating BMI1 pro-
tein stability.
FAL1 overexpression led to higher expression of BMI1 protein
in HOSE cells (Figure S4C). Consistently, compared with control
cells, FAL1-overexpressing cells had higher level of H2AK119
ubiquitination (Figure S4C). Further analysis on different subcel-
lular fractions revealed that FAL1-expressing cells had higher
BMI1 expression in all different fractions than control cells (Fig-
ure S4D). Interestingly, in response to FAL1 overexpresion, there
were also slight increases of Ring1A and Ring1B protein in the
whole-cell lysates and in different subcellular fractions. How-
ever, the changes in Ring1A/B were to a much lesser extentCathan that in BMI1 (Figure S4C). Together, these findings suggest
that the primary function of FAL1 is to stabilize BMI1, and BMI1
stabilization, we reason, may further stabilize the whole PRC1
complex, therefore causing increases in the levels of other
PRC1 core proteins.
FAL1 Regulates the Transcription of a Large
Set of Genes
BMI1 is part of the PRC1 complex, a well-characterized chro-
matin-modifying complex that represses the transcription of a
wide range of genes (Schuettengruber et al., 2007). Given that
FAL1 can bind to and stabilize BMI1 and that FAL1 expression
alteration changed the level of H2AK119 ubiquitination, we
reasoned that FAL1 expression alteration may influence BMI1
activity, which in turn can lead to genome-wide alterations in
transcription. To test this hypothesis, we analyzed the RNA
expression profiles of A2780 cells expressing shRNAs targeting
either FAL1 or BMI1. Two independent shRNA hairpins were
used for each target gene to avoid off-target effects. The tran-
scription of 732 genes (represented by 1,015 probes) was upre-
gulated by the expression of both BMI1 shRNAs in A2780 cells.
In support of our hypothesis, we found that knocking down FAL1
induced transcriptional alterations in a wide range of genes,
including 887 genes (represented by 1,019 probes) whose
expression was upregulated by both FAL1 shRNAs (Figure 5A).
Intriguingly, the expression of 641 of the 1,019 FAL1-induced
probes (62.9%) was also increased by at least one of the BMI1
shRNAs, with 285 (28%) probes induced by both BMI1 shRNAs
(Figure 5A). Only 59 (5.8%) probes were upregulated by FAL1
knockdown but downregulated by the expression of at least
one BMI1 shRNA; within these 59 probes, only four (0.4%)
were downregulated by both BMI1 shRNAs (Figure 5A). The
high degree of similarity between FAL1- and BMI1-mediated
transcriptional repression strongly indicates a functional interac-
tion between FAL1 andBMI1, and the 285 probeswhose expres-
sions was upregulated by all four hairpins (Figure 5A) may be a
common set of target genes shared by FAL1 and BMI1.
To explore the functional processes that are affected by FAL1-
mediated transcriptional regulation, we performed gene onto-
logy (GO) analysis on the 887 genes that were upregulated by
the knockdown of FAL1. The most significantly overrepresented
biological processes included pathways involved in cell prolifer-
ation, death, and survival, as well as cellular movement and pro-
tein degradation (Figure 5B; Table S10). For example, genes
involved in cell-cycle arrest and apoptosis, such as CDKN1A,
FAS, BTG2, TP53I3, FBXW7, and CYFIP2, were found to be
significantly upregulated by both FAL1 and BMI1 knockdown
in the above array studies. The increased expression of these
six target genes was further validated by qRT-PCR (Figures 5A
and 5C). Given that the PRC1 complex regulates gene transcrip-
tion by binding to promoter regions andmodifying chromatin, we
examined whether FAL1 knockdown affected BMI1 occupancy
of the promoter regions in these target genes. The effect of
FAL1 knockdown on the occupancy of BMI1 or ubiquitination
levels of H2AK119 in the target gene promoters was evaluated
using a chromatin immunoprecipitation (ChIP) assay followed
by qPCR. Among the six target genes tested, BMI1 occupancy
and ubiquitinated H2AK119 were validated in the promoter
regions of five genes, and knocking down FAL1 significantlyncer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inc. 351
Figure 5. FAL1 Regulates the Transcription of a Large Number of Genes
(A) Expression heatmap of transcripts whose expressions were upregulated by the transduction of both FAL1 shRNAs. Expression profiles of the 1,019 probes in
cells with FAL1 knockdown (left) and with BMI1 knockdown (right) are shown. The genes were ranked according to the magnitude of the fold change within the
FAL1 group. Red and green indicate up- and downregulation, respectively.
(B) The top 20 biological processes affected by FAL1 downregulation by GO.
(C) qRT-PCR validation of six genes that were upregulated by the knockdown of FAL1 and BMI1 in the microarray.
(D) The occupancy of BMI1 in the promoter regions of the above six genes was measured by BMI1 ChIP assay followed by qPCR in cells expressing control and
FAL1 shRNA. ND, not detected.
(E) PRC1 complex activity in cells expressing control and FAL1 shRNAs. The ubiquitination of H2AK119 on the promoters of its target genes were measured by
ubH2AK119 ChIP assays followed by qPCR.
Error bars indicate SD. *p < 0.05; **p < 0.01. See also Table S10.
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Oncogenic lncRNA FAL1 Represses p21 Expressionreduced the occupancy of BMI1 and ubiquitination levels of
H2AK119 on the promoter regions of these genes (Figures 5D
and 5E). These findings demonstrate that FAL1 is important in
regulating gene transcription, presumably in part by regulating
the association between BMI1 and the promoter regions of its
target genes.352 Cancer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier IncFAL1 Regulates Cell-Cycle Progression and
Senescence via the Suppression of p21 Expression
Among the common targets of FAL1 and BMI1, CDKN1A is of
particular interest because of its remarkable expression fold
change upon FAL1 knockdown (Figure 5A) and its significant
contribution to tumorigenesis. Furthermore, in ovarian tumor.
Figure 6. FAL1 Regulates Cell-Cycle Progression and Senescence via the Suppression of p21 Expression
(A) The correlation between FAL1 expression and p21 levels in ovarian cancer samples.
(B) Western blot of p21 and BMI1 in cells expressing control, FAL1 and BMI1 shRNAs.
(C) Cell-cycle profiles of cells expressing control and FAL1 shRNAs.
(D) b-Galactosidase staining of cells expressing control and FAL1 shRNAs.
(E) Cell-cycle profiles of A2780 cells expressing control and FAL1 shRNAs with and without CDKN1A shRNAs.
(F) b-Galactosidase staining of A2780 cells expressing control and FAL1 shRNAs with and without CDKN1A shRNAs.
(G) p21 protein expression of in A2780 control and FAL1 knockdown cells expressing control and CDKN1A shRNAs.
Error bars indicate SD. *p < 0.05. See also Figure S5.
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tween FAL1RNA levels and the expression of p21 in both protein
and RNA levels (Figure 6A; Figure S5). It was consistent with our
finding that CDKN1A mRNA was elevated upon FAL1 knock-
down and strongly suggests that FAL1 can negatively regulate
p21 protein expression in tumors. In support of the role of
FAL1 in the repression of p21 expression, p21 protein was signif-
icantly increased in both A2780 and MCF-7 cell lines expressing
FAL1 shRNA (Figure 6B). Because CDKN1A is a common target
of FAL1 and BMI1, the expression of p21 was also induced by
BMI1 knockdown (Figure 6B). In combination with our earlier re-
sults from ChIP assays (Figures 5D and 5E), these findings
strongly suggest that FAL1 may modulate the transcription of
CDKN1A by regulating BMI1 abundance and occupancy on
CDKN1A’s promoter.
Next, we examined if knocking down FAL1 leads to the same
two phenotypes often seen in cells with p21 overexpression:Cacell-cycle arrest and senescence. Using a BrdU incorporation
assay, we found that knocking down FAL1 expression by
shRNAs significantly induced G0/G1 arrest in both A2780 and
MCF7 cell lines (Figure 6C). This is in agreement with our previ-
ous observation that FAL1 knockdown significantly blocked
cell proliferation (Figure 2). In addition, we observed that the
expression of FAL1 shRNAs remarkably increased the number
of the cells with typical senescence morphology. We also
measured the b-galactosidase activity in cancer cells expressing
control or FAL1 shRNAs and found that the percentage of
b-galactosidase-positive cancer cells was significantly higher
in FAL1 knockdown cells than in controls (Figure 6D). Finally,
we found that knocking down p21 expression significantly
rescued the cell cycle and senescence phenotypes that were
induced by the expression of FAL1 shRNAs (Figures 6E–6G).
Together, these results demonstrate that FAL1 exerts its function
at least in part via regulating p21 expression.ncer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inc. 353
Figure 7. Reduction of FAL1 Expression by siRNA Delivery Inhibits Orthotopic Ovarian Tumor Growth in Vivo
(A) Illustration of the FAL1 siRNA treatment timeline. Arrows indicate different events (dark blue, cell injection; light blue, bioluminescent imaging; red, siRNA
treatment; yellow, tissue harvesting).
(B) Bioluminescent quantification of tumor growth of FAL1 and control siRNA-treatedmice. The first treatment is indicated by the red arrow. The x axis represents
the six rounds of optical imaging measurements.
(C) Representative bioluminescent images of animals receiving control (top) and FAL1 (bottom) siRNAs during the five rounds of treatments.
(D) Images of tumor nodes collected from animals receiving control (top) and FAL1 (bottom) siRNA 3 days after the last treatment.
(E and F) The RNA expression of FAL1 (E) and protein expression of p21 (F) in A2780 tumors.
(G) Cell proliferation in A2780 tumors. (Left) Ki67 staining; (right) quantification of the proliferation rate.
(H) The level of cleaved caspase3 in A2780 tumors.
Error bars indicate SD. *p < 0.05; **p < 0.01.
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RNA Delivery Inhibits Orthotopic Ovarian Tumor
Growth In Vivo
We next evaluated the therapeutic potential of small interfering
RNA (siRNA) that specifically targets FAL1 using an orthotopic
mouse model for late-stage ovarian cancer. Briefly, luciferase-
expressing A2780 cells were injected into the peritoneal cavity
of female nude mice. Two weeks after cell injection, mice were
randomly assigned to one of two groups to receiving either
FAL1 siRNA or control siRNA via intraperitoneal injection. Biolu-
minescent imaging was used tomonitor the tumor burden before
each round of siRNA injection (Figure 7A). Although there was a
significant increase in the intensity of luminescence in the control
siRNA-treated animals over the course of the injections, the lumi-
nescence signals in the FAL1 siRNA-treated mice decreased
significantly (Figures 7B and 7C). Consistently, the tumor nodes
from mice treated with FAL1 siRNA were much smaller and
weighed significantly less than those from the control group (Fig-
ure 7D). Consistent with in vitro observation, the p21 expression
in FAL1 siRNA-treated tumors was higher than that in control-
treated tumors (Figures 7E and 7F). Furthermore, we found
that FAL1 siRNA-treated tumors had fewer Ki67-positive cells
andmore apoptosis than controls (Figures 7G and 7H). These re-
sults not only confirm the oncogenic activity of FAL1 in vivo but354 Cancer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Incalso suggest that targeting FAL1 may represent an approach in
cancer treatment.
DISCUSSION
Before the discovery of noncoding RNAs, searches for cancer
drivers were focused on protein-coding genes that resided in
recurrent alterations in cancer genomes. However, many of
these recurrent alterations were found to either be in ‘‘gene
desert’’ regions or to contain no known cancer-causing pro-
tein-coding genes (Beroukhim et al., 2010; Zack et al., 2013).
Furthermore, although over 30% of the genome is affected by
SCNAs, only 2% of the human genome encodes proteins. These
findings, in combination with the recent revelation that about
70%of the human genome is transcribed into RNA, strongly sug-
gest that noncoding RNAs in SCNAs play significant roles in
tumor development. However, large-scale functional character-
ization of lncRNA SCNAs is still lacking (Du et al., 2013). Here, we
demonstrated that lncRNA SCNAs are common in cancer ge-
nomes; our findings also provide a plausible molecular mecha-
nism underlying the deregulation of cancer-associated lncRNA
expression in cancers.
Recent advances in high-throughput biotechnologies have led
to the exponential growth of high-resolution SCNA profiles of.
Figure 8. A Proposed Model of the Functional Consequence of FAL1 Amplification in Tumorigenesis
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Oncogenic lncRNA FAL1 Represses p21 Expressionspecimens from various types of cancer. However, because
cancer genomes are highly unstable, many cancer-associated
alterations are not the causes but instead the consequence of
tumorigenesis. The main challenge is to identify the cancer-
driving SCNAs, which, once targeted by therapeutic agents,
can suppress or eliminate tumor growth. Analyses of genome-
wide profiles using various bioinformatics approaches can reveal
associations between SCNAs and different types of cancer but
cannot distinguish ‘‘causal’’ from ‘‘bystander’’ genetic alter-
ations. Genome-wide functional screening approaches have
been used with some success in identifying cancer-driving
events; however, this approach can be time and labor intensive
and, more important, susceptible to false-positive discovery.
Here, we aimed to identify oncogenic lncRNAs using an inte-
grated strategy. The bioinformatics analyses we conducted
serve as a powerful clinical filter to eliminate lncRNAs that are
less likely to be oncogenes because of the lack of RNA expres-
sion or genetic alterations in cancer; consequently, only a sub-
group of genes with high oncogenic potential was selected for
downstream functional validation. The small size of the candi-
date gene pool, in return, allowed us to use multiple hairpins
for functional validation.
We revealed that FAL1 can interact with the PRC1 core
protein, BMI1, and that FAL1 exerts its oncogenic function at
least in part via suppressing of p21 expression (Figure 8). Previ-
ous studies have suggested that a large number of lncRNAs are
associated with chromatin-modifying complexes such as PRC2
(Khalil et al., 2009). For example, HOTAIR (Tsai et al., 2010) and
ANRIL (Kotake et al., 2011; Yap et al., 2010), two well-character-
ized oncogenic lncRNAs, both interact with PRC complexes to
regulate gene transcription. Specifically, HOTAIR, which is
known for its role in promoting tumor metastasis (Gupta et al.,
2010), binds to EZH2/PRC2 and LSD1 to coordinate their func-
tion in epigenetically regulating gene expression (Tsai et al.,
2010), while ANRIL interacts with CBX7/PRC1 (Yap et al.,
2010) and SUZ12/PRC2 (Kotake et al., 2011) to repress the tran-
scription of the tumor suppressor INK4A/INK4B. In addition, the
tumor suppressor lncRNA Xist can regulate gene expression by
tethering PRC2 to the X chromosome (Jeon and Lee, 2011). In
combination with these findings, the functional interaction be-
tween FAL1 and BMI1 that we characterized in this study further
emphasizes the centrality of lncRNA in the regulation of gene
expression and suggests that interaction with chromatic modi-
fying complexes may be an important mechanism by which
lncRNAs exert their functions.
Because a large percentage of the human genome encodes
noncoding RNAs, and lncRNAs are highly deregulated in cancer,
it is believed that lncRNAs represent a class of cancer bio-
markers and therapeutic targets whose potential has not beenCafully explored. Several studies have described specific lncRNAs
as cancer biomarkers. The most prominent example is PCA3, a
lncRNA highly expressed in prostate cancer (Lee et al., 2011).
Therapies designed to target cancer-driving lncRNAs are also
under intensive investigation. To this end, rapid advances in
oligonucleotide and nanoparticle technology create realistic
optimism for delivering siRNA-based therapeutics to regulate
lncRNA levels in vivo. Our findings warrant further investigation
about the potential of FAL1 as an informative biomarker and a
therapeutic target for patients with cancer.
EXPERIMENTAL PROCEDURES
Patient Specimens
Ovarian cancer specimens were collected at the University of Turin. Speci-
mens were acquired and processed under procedures approved by the
University of Pennsylvania and University of Turin institutional review boards.
SNP Data Retrieval and Analysis
The raw data from SNP microarrays were downloaded from the Tumorscape
database created by the Broad Institute. CEL files were extracted using the Af-
fymetrix Genotype software and analyzed using the Partek Genomics Suite
software package. The 158 independent focal genomic alteration peaks and
the numbers of protein-coding genes in each peak were previously identified
by the Tumorscape Project based on 3,131 cancer specimens of 26 histolog-
ical types (Beroukhim et al., 2010). Please see Supplemental Experimental
Procedures for a discussion of detailed procedures.
shRNA Screening and Lentiviral Transduction
Lentiviral vector (pLKO.1) and packaging vectors were transfected into 293T
cells. The medium was changed 8 hr after transfection, and the medium con-
taining lentivirus was collected 48 hr later. Cancer cells were infected with
lentivirus in the presence of 8 mg/ml polybrene.
RNA Isolation and qRT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen) and reverse tran-
scribed using the High Capacity RNA-to-cDNA Kit (Applied Biosystems).
cDNA was quantified by an ABI ViiA 7 System (Applied Biosystems).
RNA Pull-Down Assay
The FAL1 cDNA was cloned into pBluescript II vector. Biotin-labeled RNAs
were transcribed in vitro and purified. Cell nuclei were harvested and resus-
pended in freshly prepared polysome lysis buffer. Biotinylated RNA (10
pmol) was mixed with 200 mg of nuclear lysate and thenmixed with prewashed
streptavidin-agarose beads for 1 hr. The beads were washed with ice-cold
NT2 buffer five times and then boiled with 2x Laemmli loading buffer.
Xenograft Model In Vivo
Six- to eight-week-old female nude mice were used for the xenograft experi-
ments. Cancer cells were trypsinized and harvested in PBS, and a total volume
of 0.1 ml PBS was injected subcutaneously into the flanks or intraperitoneally
into the peritoneal cavity. The jetPEI reagent (Polyplus Transfection) was used
to deliver the siRNAs in vivo. The animal study protocol was reviewed andncer Cell 26, 344–357, September 8, 2014 ª2014 Elsevier Inc. 355
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Oncogenic lncRNA FAL1 Represses p21 Expressionapproved by the Institutional Animal Care andUse Committee of the University
of Pennsylvania.
Statistical Analysis
Results are expressed as mean ± SD, and p < 0.05 indicates significance. The
survival curves were constructed according to the Kaplan-Meier method and
compared with the log-rank test.
ACCESSION NUMBER
Themicroarray data are accessible in the Gene Expression Omnibus database
under accession number GSE52210.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and ten tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.07.009.
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